J.P. Morgan reiterated its WuXi PharmaTech WX Overweight rating and $23 price target in a research report published today.
In the report, J.P. Morgan states, "Following the January (1/10) pre-announcement of 4Q revenues and operating margins above guidance, 4Q results provided few surprises, while 2011 revenue guidance was in line with expectations with a slightly lower bottom line reflecting a possible tax rate increase and wage inflation. Given the strong 2010 results and healthy long-term fundamentals, we expect that investors will look beyond nearterm headwinds from a higher tax rate and wage inflation. Importantly, we believe that there is potential to exceed guidance in a number of areas in 2011, including manufacturing revenues (driven by telaprevir), U.S.-based revenues (which had a solid 2010), and gross and operating margins."
Shares of WuXi PharmaTech closed Wednesday at $16.87, up 5.77% from Tuesday's market close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.